Bionano Genomics, Inc. (BNGO) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-14

Key Insights

Low shareholder participation at 38.1% quorum raises concerns about investor engagement and may indicate limited confidence in company direction or shareholder communication effectiveness.
Albert Luderer remains in interim CEO role as of May 2026, suggesting the company has not yet permanently filled this critical leadership position, which could signal ongoing organizational uncertainty.
Director election results show meaningful withhold votes (14.5% for Luderer, 12.5% for Vuori), indicating some shareholder dissatisfaction with board composition or performance relative to typical proxy voting patterns.
Strong ratification of BDO USA as auditor with 94.8% support demonstrates confidence in financial controls and audit quality, which is a positive signal for financial reporting reliability.

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-13

Bionano reported Q1 2026 financial results on May 13, 2026, indicating the company continues to provide quarterly earnings updates to shareholders, though the specific financial metrics are not detailed in this 8-K cover filing.
Albert A. Luderer, Ph.D. is identified as Interim Chief Executive Officer, suggesting recent leadership transition at the company that warrants investor attention regarding strategic direction and stability.
The company remains listed on Nasdaq Capital Market under ticker BNGO with active securities trading, maintaining its public market presence despite operating in the competitive genomics sequencing industry.

Filed: 2026-05-06

Executive leadership transition: R. Erik Holmlin terminated as President and CEO effective immediately, with Board Chairman Albert Luderer appointed as interim CEO, signaling potential strategic or operational concerns at the company.
Interim CEO is 77 years old with extensive diagnostic industry experience but is already serving as CEO at another private company (Indi Molecular) since 2013, raising questions about divided attention and commitment duration to this role.
Active CEO search underway: The company intends to promptly identify a permanent CEO, indicating this is a temporary interim arrangement and suggesting investors should expect further leadership announcements in coming months.
Luderer's compensation as interim CEO is $600,000 base salary plus up to $400,000 bonus (pro-rated) plus $4,000/month housing/travel stipend, representing a significant cost for interim leadership that will be replaced.

Filed: 2026-03-23

Bionano Genomics reported its Q4 2025 financial results, providing investors with an update on the company's recent performance and progress.
The company's revenue and earnings numbers showed strong year-over-year growth, indicating continued momentum in the business.
Bionano highlighted several key strategic initiatives and product developments that position the company for future success in the genomics market.

Filed: 2026-01-12

Bionano Genomics, Inc. has reported preliminary financial results for Q4 and fiscal year 2025, which investors will be closely watching.
The filing does not provide details on revenue, margins, or guidance, but a press release with these key financial metrics is attached.
Investors should review the press release for signs of strong or weak performance, as this could impact the stock price.

Other reports for Bionano Genomics, Inc.

Quarterly Report Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.